000131758 001__ 131758
000131758 005__ 20240229105011.0
000131758 0247_ $$2doi$$a10.1002/ijc.31058
000131758 0247_ $$2pmid$$apmid:28921520
000131758 0247_ $$2pmc$$apmc:PMC5749630
000131758 0247_ $$2ISSN$$a0020-7136
000131758 0247_ $$2ISSN$$a1097-0215
000131758 0247_ $$2altmetric$$aaltmetric:26312170
000131758 037__ $$aDKFZ-2018-00057
000131758 041__ $$aeng
000131758 082__ $$a610
000131758 1001_ $$00000-0002-9887-2389$$aJung, Seungyoun$$b0
000131758 245__ $$aAnti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
000131758 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000131758 3367_ $$2DRIVER$$aarticle
000131758 3367_ $$2DataCite$$aOutput Types/Journal article
000131758 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521456589_14509
000131758 3367_ $$2BibTeX$$aARTICLE
000131758 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131758 3367_ $$00$$2EndNote$$aJournal Article
000131758 520__ $$aAnimal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
000131758 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000131758 588__ $$aDataset connected to CrossRef, PubMed,
000131758 650_7 $$2NLM Chemicals$$aBiomarkers
000131758 650_7 $$080497-65-0$$2NLM Chemicals$$aAnti-Mullerian Hormone
000131758 7001_ $$aAllen, Naomi$$b1
000131758 7001_ $$aArslan, Alan A$$b2
000131758 7001_ $$aBaglietto, Laura$$b3
000131758 7001_ $$aBarricarte, Aurelio$$b4
000131758 7001_ $$00000-0003-3853-8562$$aBrinton, Louise A$$b5
000131758 7001_ $$aEgleston, Brian L$$b6
000131758 7001_ $$aFalk, Roni T$$b7
000131758 7001_ $$00000-0002-1426-8505$$aFortner, Renée T$$b8
000131758 7001_ $$aHelzlsouer, Kathy J$$b9
000131758 7001_ $$aGao, Yutang$$b10
000131758 7001_ $$aIdahl, Annika$$b11
000131758 7001_ $$0P:(DE-HGF)0$$aKaaks, Rudolph$$b12
000131758 7001_ $$00000-0003-0122-8624$$aKrogh, Vittorio$$b13
000131758 7001_ $$aMerritt, Melissa A$$b14
000131758 7001_ $$aLundin, Eva$$b15
000131758 7001_ $$aOnland-Moret, N Charlotte$$b16
000131758 7001_ $$aRinaldi, Sabina$$b17
000131758 7001_ $$0P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aSchock, Helena$$b18$$udkfz
000131758 7001_ $$aShu, Xiao-Ou$$b19
000131758 7001_ $$aSluss, Patrick M$$b20
000131758 7001_ $$aStaats, Paul N$$b21
000131758 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b22
000131758 7001_ $$aTravis, Ruth C$$b23
000131758 7001_ $$aTjønneland, Anne$$b24
000131758 7001_ $$aTrichopoulou, Antonia$$b25
000131758 7001_ $$aTworoger, Shelley S$$b26
000131758 7001_ $$aVisvanathan, Kala$$b27
000131758 7001_ $$aWeiderpass, Elisabete$$b28
000131758 7001_ $$aZeleniuch-Jacquotte, Anne$$b29
000131758 7001_ $$aDorgan, Joanne F$$b30
000131758 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31058$$gVol. 142, no. 2, p. 262 - 270$$n2$$p262 - 270$$tInternational journal of cancer$$v142$$x0020-7136$$y2018
000131758 909CO $$ooai:inrepo02.dkfz.de:131758$$pVDB
000131758 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-1426-8505$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000131758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000131758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1bd6298f721e4a01f21c2329276a53a7$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000131758 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000131758 9141_ $$y2018
000131758 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131758 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131758 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131758 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131758 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000131758 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131758 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131758 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131758 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131758 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000131758 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131758 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000131758 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000131758 980__ $$ajournal
000131758 980__ $$aVDB
000131758 980__ $$aI:(DE-He78)C020-20160331
000131758 980__ $$aUNRESTRICTED